Recurrence of mesenteric vascular occlusion in patients with essential thrombocythemia

Sung Min Jung and Heungman Jun

Abstract

Essential thrombocythemia is a myeloproliferative neoplasm characterized by platelet aggregation and thrombosis. Clinically, essential thrombocythemia increases the risk of both thrombosis and bleeding. Essential thrombocythemia is more involved in micro- and small-sized arteries than in large arteries. Many essential thrombocythemia patients exhibit various symptoms, including microvascular thrombosis with acute coronary disease, digital ischemia, and transient ischemic attack. This study reports a rare case of recurrent thrombosis in relatively large vessels including splanchic, lower extremity arteries, and aorta in essential thrombocythemia. A 70-year-old woman was admitted to the emergency room with abdominal pain and fever for a day. The patient underwent three operations due to recurrent arterial thrombosis of superior mesenteric, splenic, aorta, and lower extremities. She had recurrent diarrhea and acute kidney injury because of short bowel syndrome after extensive bowel resection. In conclusion, essential thrombocythemia patients aged >60 years and who have risk factors such as history of major ischemic events or severe leukocytosis must be careful of thrombosis of the medium- and large-sized arteries, including splanchic and lower extremity arteries.

Keywords

Essential thrombocythemia, mesenteric vascular occlusion, mesenteric ischemia

Date received: 8 April 2019; accepted: 10 September 2019

Introduction

Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by platelet aggregation and thrombosis. Clinically, ET increases the risk of both thrombosis and bleeding. The other features of ET include leukocytosis, splenomegaly, microcirculatory disturbance, pruritus, and leukemic transformation. Sometimes ET is detected later on in patients with thrombosis. The annual incidence of ET was 0.38–1.7 per 100,000, and thrombotic complications occur in 6.6% of ET patients per year.

ET is more involved in micro- and small-sized arteries than in large arteries. Thrombosis in ET patients is usually presented in the cerebral, coronary, and peripheral arteries. Many ET patients exhibit various symptoms, including microvascular thrombosis with acute coronary disease, digital ischemia, and transient ischemic attack.

Here, we report a rare case of recurrent thrombosis in relatively large vessels, including splanchic, lower extremity arteries, and aorta in ET.

Case report

A 70-year-old Korean woman was admitted to the emergency room by ambulance with abdominal pain and fever for a day. She had a history of hypertension without any antithrombotic agents. Her vital signs were stable. At admission, complete blood count (CBC) revealed a white blood cell count of 49.83 × 10^3 mm^-3, with 75% neutrophils and 3% lymphocytes; platelet volume of 1122 × 10^3 mm^-3, and red cell count of 13.8 mm^-3. The final diagnosis was essential thrombocythemia. Other laboratory findings showed an elevated creatinine kinase (CK) of 585 U/L, amylase of 117 U/L, and procalcitonin of 6.85 ng/mL. Conversely, laboratory findings, including hepatic...
renal function, coagulation, cholesterol, and blood glucose, were within normal limits. The patient had severe abdominal pain with tenderness of the whole abdomen. Abdominopelvic computed tomography (CT) revealed superior mesenteric artery (SMA) thrombosis, jejunal necrosis of long range, and splenic infarction (Figure 1). Emergency operation, consisting of jejunal resection of about 1 m, splenectomy, and double barrel jejunostomy, was performed in the surgical department. Double barrel jejunostomy was performed to check any remnant unhealthy jejunum tissue and to prevent anastomotic leakage.

Oral intake was initiated 4 days after surgery, and the patient was stabilized. Bone marrow biopsy showed ET with hypercellular bone marrow and megakaryocytosis. Chromosomal study revealed JAK2 gene mutation at V617F. In postoperative echocardiography, ejection fraction maintained normal without cardiac wall motion defect and arrhythmia. Because of uncontrolled platelet count, the patient took anagrelide and hydroxyurea together with a hematology consultation, postoperatively. Aspirin could not be used due to persistent intraperitoneal bleeding. The patient was discharged without any complications after 2 weeks with hydroxyurea and aspirin.

One month after the first operation, the patient complained of pain in left leg for 2 days. In CT angiography, the femoropopliteal artery was occluded with thrombosis (Figure 2). Emergency thrombectomy with cut-down of femoral and popliteal artery was performed; however, recanalization was unsuccessful due to the failure of catheter passage. Bypass from superficial femoral to below-knee popliteal artery was performed using a reversed saphenous vein graft. After 10 days, the patient was discharged without leg pain and prescribed with anagrelide and warfarin.

One month after surgery to the lower extremities, the patient visited the emergency room with a new complaint of abdominal pain. Abdominopelvic CT revealed thrombosis of SMA branches, jejunal necrosis, and floating thrombus of the abdominal aorta (Figure 3). Jejunal resection of 1 m and double barrel jejunostomy were performed again. She had recurrent diarrhea and acute kidney injury because of short

---

**Figure 1.** Enhanced CT scan before the first abdominal surgery: (a) white arrow indicates superior mesenteric artery thrombosis and (b) arrow with white border indicates splenic infarction.

**Figure 2.** Lower extremity CT angiography revealing the artery below superficial femoral artery occluded with thrombosis.
bowel syndrome after extensive small bowel resection and died 1 year after last operation.

**Discussion**

ET is more common in micro- and small-sized arteries than in large arteries. Previous research showed altered regulation of peripheral circulation, including increased resistance and decreased flow. These circulatory disorders were usually confined to the distal arterial bed and the division of the digital arteries. There are some reports of large-vessel thrombosis that required surgery, but such cases are very rare. More cases of ET patients accompanied by aortic thrombosis or splenic infarction are also unusual. However, recent meta-analysis on ET failed to uncover any notable association between JAK2 mutation and microcirculatory disorders. More research is needed in clinical pathophysiology of ET-related vasculopathy.

ET patients show various clinical manifestations, depending on the patients’ risk factors as well as the involved vessels. Carrobio et al. reported that predictors of arterial thrombosis included age >60 years, thrombosis history, cardiovascular risk factors including tobacco use, hypertension, or diabetes mellitus, leukocytosis, and presence of JAK2 V617F. Moreover, Besses et al. also reported that age >60 years and history of major ischemic events may be risk factors of atherothrombotic complications in ET patients. In addition, white blood cell count >104 mm$^{-3}$ is a risk factor for thrombosis. In this study, recurrent ischemic events and severe leukocytosis were presented in patients aged >60 years. Recurrent occlusions of superior mesenteric, splenic, and femoropopliteal arteries support thrombotic etiologies of ET without cardiac arrhythmia in this study.

**Conclusion**

Here, we reported a rare case of recurrent thrombosis in relatively large vessels, including splanchnic, lower extremity arteries, and aorta with ET. ET patients aged >60 years and who have risk factors such as history of major ischemic events or severe leukocytosis must be careful of thrombosis of the medium- and large-sized arteries, including splanchnic and lower extremity arteries.

**Author contributions**

S.M.J. contributed in data collection, review of patient history and surgical records, and writing papers. H.J. contributed in the review and control of study concept and design, review of discussion, and writing papers.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Ethical approval**

The Institutional Review Board (IRB) of the Inje University Ilsan Paik Hospital approved the review of patient records and this study. The number from IRB is 2019-01-027.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Figure 3.** Enhanced CT scan before the second abdominal surgery: (a) white arrow indicates the floating emboli of abdominal aorta and (b) arrow with white border indicates superior mesenteric artery thrombosis.
Guarantor
Heungman Jun, MD, PhD (midasia@hanmail.net).

Informed consent
Written informed consent was obtained from a legally authorized representative(s) for anonymized patient information to be published in this article. The patient was already dead and we received written consent from guardian.

ORCID iD
Heungman Jun https://orcid.org/0000-0003-2530-4388

References
1. Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006; 107(11): 4214–4222.
2. Tefferi A and Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 2019; 94(1): 133–143.
3. Tefferi A, Thiele J and Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009; 115(17): 3842–3847.
4. Petrides PE and Siegel F. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles. Blood Cells Mol Dis 2006; 36(3): 379–384.
5. Johnson M, Gernsheimer T and Johansen K. Essential thrombocytosis: underemphasized cause of large-vessel thrombosis. J Vasc Surg 1995; 22(4): 443–447; discussion 448–449.
6. Rossi C, Randi ML, Zerbinati P, et al. Acute coronary disease in essential thrombocythemia and polycythemia vera. J Intern Med 1998; 244(1): 49–53.
7. Colombi M, Radaelli F, Zocchi L, et al. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 1991; 67(11): 2926–2930.
8. Malecki R, Gacka M, Fiodoreiko-Dumas Z, et al. Peripheral circulatory disorders in essential thrombocythemia. Microvasc Res 2018; 116: 15–19.
9. Yuan J, Wu Y, Hao J, et al. The comorbidity of acute ischemic stroke and splenic infarction resulting from essential thrombocythemia. Neurol Sci 2018; 39(10): 1787–1790.
10. Qin Y, Wang X, Zhao C, et al. The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis. Int J Hematol 2015; 102(2): 170–180.
11. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117(22): 5857–5859.
12. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999; 13(2): 150–154.
13. Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008; 26(16): 2732–2736.